Login to Your Account



ViroPharma's Profit Falls

Cinryze's Just-in-Time Win Soothes Vancocin Worries

By Jennifer Boggs


Thursday, July 30, 2009
As it faces a steep decline in revenue from potential generic threats to its top-selling drug Vancocin, ViroPharma Inc. impressed investors and analysts with higher-than-expected second-quarters sales of hereditary angioedema drug Cinryze. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription